Peer-reviewed veterinary case report
How trilostane and mitotane affect aldosterone in dogs with pituitary
By Reid, L E et al.·Published in Journal of veterinary internal medicine·2014·Department of Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effect of trilostane and mitotane on aldosterone secretory reserve in dogs with pituitary-dependent hyperadrenocorticism.
- Species:
- dog
Plain-English summary
A group of dogs with pituitary-dependent hyperadrenocorticism (a condition causing excess cortisol) were treated with either trilostane or mitotane to see how these medications affected their aldosterone levels after an ACTH stimulation test. The results showed that many of these dogs had lower aldosterone levels compared to healthy dogs, particularly at the 30-minute mark after the test. In fact, nearly half of the dogs treated with trilostane and a significant majority treated with mitotane showed decreased aldosterone secretory reserve. This suggests that while these treatments help manage hyperadrenocorticism, they may also impact aldosterone production, which isn't always reflected in electrolyte levels.
People also search for: dog hyperadrenocorticism treatment · trilostane side effects in dogs · mitotane for dog Cushing's disease
Abstract
BACKGROUND: Maximal aldosterone secretion in healthy dogs occurs 30 minutes postadrenocorticotropin (ACTH; 5 μg/kg IV) stimulation. The effect of trilostane and mitotane on aldosterone at that time is unknown. OBJECTIVES: To assess the effect of trilostane and mitotane in dogs with pituitary-dependent hyperadrenocorticism on aldosterone secretory reserve. To determine if aldosterone concentration correlates with electrolyte concentrations. ANIMALS: Serum collected from 79 client-owned dogs and 33 stored samples. METHODS: Client-owned dogs had ACTH stimulation tests with cortisol concentrations measured at 0 and 60 minutes and aldosterone concentrations measured at 0, 30, and 60 minutes. Stored samples had aldosterone concentrations measured at 0 and 60 minutes. Ten historical clinically healthy controls were included. All had basal sodium and potassium concentrations measured. RESULTS: The aldosterone concentrations in the mitotane- and trilostane-treated dogs at 30 and 60 minutes post-ACTH were significantly lower than in clinically healthy dogs; no significant difference was detected in aldosterone concentration between 30 and 60 minutes in treated dogs. However, a significantly higher percentage of dogs had decreased aldosterone secretory reserve detected at 30 minutes than at 60 minutes. At 30 minutes, decreased secretory reserve was detected in 49% and 78% of trilostane- and mitotane-treated dogs, respectively. No correlation was detected between aldosterone and serum electrolyte concentrations. CONCLUSIONS AND CLINICAL IMPORTANCE: Decreased aldosterone secretory reserve is common in trilostane- and mitotane-treated dogs; it cannot be predicted by measurement of serum electrolyte concentrations. Aldosterone concentration at 30 minutes post-ACTH stimulation identifies more dogs with decreased aldosterone secretory reserve than conventional testing at 60 minutes.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/24400747/